# Flunarizine for Treatment Resistant Absence Epilepsy

> **NCT06153186** · PHASE2 · TERMINATED · sponsor: **University of British Columbia** · enrollment: 9 (actual)

## Conditions studied

- Childhood Absence Epilepsy
- Juvenile Absence Epilepsy
- Juvenile Myoclonic Epilepsy

## Interventions

- **DRUG:** Flunarizine Hydrochloride

## Key facts

- **NCT ID:** NCT06153186
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-20
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-05-26
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The enrollment wasn't as predicted. We didn't have enough numbers to show statistical significance.
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153186, "Flunarizine for Treatment Resistant Absence Epilepsy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06153186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*